RPRXRoyalty Pharma plc

Nasdaq royaltypharma.com


$ 28.40 $ -0.35 (-1.22 %)    

Friday, 03-May-2024 15:59:58 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 28.41
$ 28.44
$ 0.00 x 0
$ 0.00 x 0
$ 28.14 - $ 28.60
$ 25.54 - $ 34.73
2,169,369
na
17.13B
$ 0.63
$ 15.09
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-15-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 02-15-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 02-15-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-11-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 02-24-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-12-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 amgen-reports-better-than-expected-q1-results-50m-milestone-payment

Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company s...

Core News & Articles

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced a $50 million milestone payment was received from Royalty Pharma ...

 b-of-a-securities-maintains-buy-on-royalty-pharma-lowers-price-target-to-38

B of A Securities analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and lowers the price target from $...

 royalty-pharma-q4-sales-59600m-miss-67365m-estimate-net-income-attributable-to-royalty-pharma-494m-versus-loss-of-456m-year-ago

Royalty Pharma (NASDAQ:RPRX) reported quarterly sales of $596.00 million which missed the analyst consensus estimate of $673.65...

 earnings-scheduled-for-february-15-2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

 royalty-pharma-announces-quarterly-dividend-increase-from-020-to-021

Reflecting a 5% increase in the company's quarterly dividend over the previous quarter's dividend. Reflecting a 5% incr...

Core News & Articles

NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital ManagementProvides Evidence That Each of...

 morgan-stanley-maintains-overweight-on-royalty-pharma-raises-price-target-to-57

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target fr...

 earnings-scheduled-for-november-8-2023

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

 royalty-pharmas-earnings-outlook
Royalty Pharma's Earnings Outlook
11/07/2023 14:01:01

Core News & Articles

The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Roy...

 morgan-stanley-maintains-overweight-on-royalty-pharma-raises-price-target-to-54

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target fr...

 stocks-that-hit-52-week-lows-on-thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION